Neuren Pharmaceuticals Updates on Securities Buy-Back

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.

Neuren Pharmaceuticals Limited has announced an update regarding its ongoing buy-back of ordinary fully paid securities, with a total of 3,590,368 securities bought back before the previous day and an additional 7,612 securities bought back on the previous day. This buy-back initiative reflects the company’s strategic move to manage its capital structure and potentially enhance shareholder value by reducing the number of shares outstanding.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of drugs for neurological disorders. The company is known for its work on therapies targeting conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.

Average Trading Volume: 771,697

Technical Sentiment Signal: Hold

Current Market Cap: A$1.64B

For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.